ongoing

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

6 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

6 months ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

6 months ago
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) AmyloidosisIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

6 months ago
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) AmyloidosisIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

6 months ago
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare ConferencesBioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

November 08, 2024 11:03 ET | Source: BioPorto A/S 8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch…

6 months ago
Show previous Posts